BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding BioCardia, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 18 | 20 | +2 |
| Shares | 427.1K | 649.6K | +222.5K (+52.1%) |
| Value | $551.9K | $812.3K | +$260.4K (+47.2%) |
New holders (4)
Institutions that held BioCardia, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 94,247 | $117.8K | 0.00% |
| DRW Securities, LLC | 57,607 | $72.0K | 0.01% |
| Two Sigma Investments, LP | 11,229 | $14.0K | 0.00% |
| Gsa Capital Partners LLP | 11,303 | $14.0K | 0.00% |
Sold out (2)
Institutions that held BioCardia, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Two Sigma Securities, LLC | 19,337 | $24.9K |
| Citigroup Inc | 833 | $1.07K |